These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33482590)

  • 1. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab.
    Pedotti R; Muros-Le Rouzic E; Raposo C; Schippling S; Jessop N
    Mult Scler Relat Disord; 2021 Oct; 55():103203. PubMed ID: 34411984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab.
    Thornton JR; Harel A
    Mult Scler Relat Disord; 2020 Sep; 44():102341. PubMed ID: 32622338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series.
    De Mercanti SF; Vercellino M; Bosa C; Alteno A; Schillaci V; Clerico M; Cavalla P
    Front Neurol; 2021; 12():691616. PubMed ID: 34744958
    [No Abstract]   [Full Text] [Related]  

  • 9. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab.
    Habek M; Piskač D; Gabelić T; Barun B; Adamec I; Krbot Skorić M
    Mult Scler Relat Disord; 2022 Jun; 62():103798. PubMed ID: 35429819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
    Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
    Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
    JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
    Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
    Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.
    Erdogan T; Cansu C; Kocer B; Akkaya S; Kokmen H
    Acta Neurol Belg; 2024 Aug; 124(4):1385-1391. PubMed ID: 38769274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
    Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
    Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
    S G; S L; C Z; A N; M F; L M
    J Neurol; 2022 Jan; 269(1):39-43. PubMed ID: 34189719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
    Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
    Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.